M.D. Akin Kürklü Board-certified internal medicine physician with clinical training completed at Şişli Etfal Training and Research Hospital (2002). Extensive experience within the Acıbadem Health Group since 2009, delivering comprehensive care with a focus on metabolic and endocrine disorders. Active member of national and international diabetes and metabolic organizations, including the Marmara Diabetes Group, Turkish Diabetes Foundation, Metabolic Syndrome Association, Turkish Diabetes Association, and the European Association for the Study of Diabetes. Committed to evidence-based practice, multidisciplinary collaboration, and improving outcomes for patients with diabetes and metabolic syndrome.
Education
- 2002 Şişli Etfal Training and Research Hospital Internal Medicine
- 1997 Istanbul University Cerrahpasa Faculty of Medicine
Experience
- 2009 Acibadem Health Group
- 2008 – 2009 Medikal Park Hospitals Group
- 2006 – 2007 Baskent University Research Hospital
- 2002 – 2006 Sisli Etfal Training and Research Hospital
Memberships
- Marmara Diabetes Group
- Turkish Diabetes Foundation
- Metabolic Syndrome Association
- Turkish Diabetes Association
- European Association for the Study of Diabetes
Publications
- Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination.
Renal Failure 2006;28(2):125-8 Basturk T, Altuntas Y, Kurklu A, Aydin L, Eren N, Unsal A. - Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Diabetes Res Clin Pract. 2006 Feb;71(2):210-9 Sengul A.M, Altuntas Y, Kurklu A, Aydin L. - Improving Metabolic Control with Lispro Therapy in Type 1 Diabetes: The Importance of Basal Insulin.
Diabet Bilimi 2004;1:15-18 Şengül A.M, Sargın M, Kürklü A, Sargın H, Canberk E, Uçak S, Ersoy Ç.Y, Argon D, Altuntaş Y. - Effects of Statins on Microalbuminuria in Patients with Type 2 Diabetes Mellitus
Diabet Bilimi 2004;4:186-191. Aydın L, Kürklü A, Uçak S, Şengül A.M, Ersoy Ç.Y, Altuntaş Y. - Comparison of the effects of carvedilol and metoprolol treatments on insulin resistance and serum lipids in patients after myocardial infarction.
Şeh Medical Bulletin 38:1-2004 Basat O, Uçak S, Öztekin E, Şeber S, Kürklü A, Argon D, Altuntaş Y. - Comparison of PAI-1 and Fibrinogen Levels in Patients with Acute Myocardial Infarction.
Şeh Medical Bulletin 45:3-2004 Kürklü A, Aydın L, Şengül A.M, Uçak S, Altuntaş Y. - Rosiglitazone therapy added to oral antidiabetic combinations or insulin therapy provides metabolic control in type 2 diabetics.
Şeh Medical Bulletin 38:1-2004 Uçak S, Basat O, Şeber S, Kürklü A, Ersoy Ç.Y, Altuntaş Y. - Acarbose Treatment Added to Other Group Oral Antidiabetics Provides Metabolic Control in the First 6 Weeks.
Şeh Medical Bulletin 37:3-2003 Uçak S, Basat O, Seber S, Ersoy Ö, Şengül A.M, Kürklü A, Baştürk T, Altuntaş Y.
